SRI International Receives $9 Million Contract to Support National Cancer Institute PREVENT Cancer Program

Nov 02, 2015, 14:30 ET from SRI International

MENLO PARK, Calif., Nov. 2, 2015 /PRNewswire/ -- SRI International has been awarded a contract of up to $9 million to provide preclinical development services to the National Cancer Institute (NCI) PREVENT Cancer Program (PCP). Under the contract, SRI will provide scientific expertise, modern testing and support facilities, and analytical instrumentation to conduct a wide variety of preclinical pharmacology and toxicology studies to evaluate potential cancer prevention drugs.

The PREVENT Cancer Drug Development Program is an NCI-supported pipeline to bring new cancer preventing interventions and biomarkers through preclinical development towards clinical trials. PREVENT enables milestone-driven progression of novel cancer preventive chemical or biological agents and biomarkers from the laboratory bench towards proof-of-principle clinical testing and registration or validation.

"We welcome the opportunity to provide preclinical toxicology and pharmacology services to support the NCI's PREVENT program," said Toufan Parman, Ph.D., D.A.B.T, director, General Toxicology, SRI Biosciences, and principal investigator for the NCI contract. "We've provided such services to the NCI for the past 23 years, and look forward to continue applying our expertise to this important work."

The current contract calls for SRI to deliver high-quality laboratory data to support NCI-PCP's efforts to develop promising therapeutic candidates such as vaccines and cancer chemopreventive agents that will inhibit, delay or reverse manifestations of cancer. SRI will be responsible for managing therapeutic candidates from conception to submission of an Investigational New Drug (IND) application to the US Food and Drug Administration. SRI has broad experience with similar studies for NCI and for many other divisions of the National Institutes of Health, as well as for private sponsors.

This effort is fully funded by the National Cancer Institute.

About SRI Biosciences
SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. SRI International, a research center headquartered in Menlo Park, California, creates world-changing solutions making people safer, healthier, and more productive.

 

SOURCE SRI International



RELATED LINKS

www.sri.com